CROI 2016 Program at a Glance

Program and Agenda

941 Lower Mortality Among Patients Starting ART From 2008 to 2010 Than Earlier in the ART Era AdamTrickey 1 ; Margaret May 1 ; Julia Del Amo 2 ; Niels Obel 3 ; Heidi M. Crane 4 ; Sophie Abgrall 5 ; Colette Smith 6 ; Suzanne Ingle 1 ; Jonathan Sterne 1 ; for the AntiretroviralTherapy Cohort Collaboration 1 UnivofBristol,Bristol,UK; 2 InstdeSaludCarlos III,Madrid,Spain; 3 CopenhagenUnivHosp,RigsHospet,Copenhagen,Denmark; 4 Univof Washington,Seattle,WA,USA; 5 UnivHospAntoine-Béclère,Clamart, France; 6 UnivCollLondon,London,UK 942 Impact of Each Month Delay in Initiation on the Effect of 1 Year of ART on CD4 Count ShuYang 1 ; Susan J. Little 2 ; Davey M. Smith 2 ;Victor De Gruttola 1 ; Judith Lok 1 1 HarvardSchofPH,Boston,MA,USA; 2 UnivofCaliforniaSanDiego, SanDiego,CA,USA 943 Outcomes on CART in France According to Geographic Origin, Sex, and Transmission Group Laure-Amélie de Monteynard 1 ; Jacques Gilquin 2 ; Juliette Pavie 3 ; Jean-Luc Meynard 4 ; Marie-Aude Khuong 5 ; Anne Simon 6 ; Aba Mahamat 7 ; David Rey 8 ; Dominique Costagliola 9 ; Sophie Abgrall 10 1 InstPierreLouisd’EpidémiologieetdeSantéPublique (IPLESP)UMR-S 1136,Paris,France; 2 HospHôtelDieu,Paris,France; 3 HospEuropéen GeorgesPompidou,Paris,France; 4 APHP,HospSaintAntoine,Paris, France; 5 HospDelafontaine,Paris,France; 6 LaPitiéSalpêtrièreHosp, Paris,France; 7 CntrHospierAndréeRosemon,Cayenne,France; 8 Hôpitaux UniversitairesdeStrasbourg,Strasbourg,France; 9 SorbonneUnivs,Paris, France; 10 UnivHospAntoine-Béclère,Clamart,France 944 CD4 Cell Response to First-Line cART by HIV Type in European Cohort Collaborations LindaWittkop 1 ; Sophie Matheron 2 ; for the COHERE in EuroCoord and ACHIeV2e study teamwriting committee 1 CHUdeBordeaux,Bordeaux,France; 2 HospBichat-ClaudeBernard, Paris,France 945 Efficiency (Cost-Effectiveness) of EFV/FTC/TDF vs FTC/ RPV/TDF in Naïve Patients Jose M. Gatell 1 ; Elisa de Lazzari 2 ; Enrique Redondo 3 ; Jose Mallolas 2 ; Esteban Martinez 2 ; Jordi Blanch 2 ; Maria Martinez-Rebollar 2 ; Jose L. Blanco 2 ; BertaTorres 2 1 HospClinicofBarcelona,Barcelona,Spain; 2 HospClínicdeBarcelona, Barcelona,Spain; 3 GileadScis, Inc,Madrid,Spain 946 Correlations of Pre-ART HIV-DNAWith Outcome in First-Line Treated ART Patients Francesca Ceccherini-Silberstein 1 ; Alessandro Cozzi-Lepri 2 ; Esther Merlini 3 ; Giulia Marchetti 4 ; Maria R. Capobianchi 5 ; Andrea De Luca 6 ; Nicola Gianotti 7 ; Andrea Antinori 5 ; Carlo Federico Perno 8 ; Antonella d’Arminio Monforte 9 ; for the ICONA Foundation 1 UnivofRomeTorVergata,Rome, Italy; 2 UnivCollLondon,London, UK; 3 UnivofMilan,milan, Italy; 4 Clinicof InfectiousDiseases,Univof Milan,SanPaoloHosp,Milan, Italy; 5 InstNazionaleMalattie Infettive “L.Spallanzani”,Rome, Italy; 6 UnivofSiena,Siena, Italy; 7 SanRaffaele Scientific Inst,Milan, Italy; 8 UnivofRomeTorVergata,Roma, Italy; 9 InfectiousDiseasesClinic,SanPaoloHosp,UnivofMilan,Milan, Italy

947 Comparable Viral Decay in Dual and Triple Dolutegravir-Based Antiretroviral Therapy

Omar G. Sued 1 ; Maria I. Figueroa 1 ; Maria J. Rolon 1 ; Patricia Patterson 2 ; Dannae Brown 3 ; Ana M. Gun 4 ; Michael Aboud 5 ; KimberleyY. Smith 6 ; Pedro Cahn 1 1 FundaciónHuésped,BuenosAires,Argentina; 2 Hosp JuanA.Fernández, BuenosAires,Argentina; 3 ViiVHlthcare,Abbotsford,Australia; 4 Centro MedicoHuesped,BuenosAires,Argentina; 5 ViiVHlthcare,Brentford,UK; 6 ViiVHlthcare,ResearchTrianglePark,NC,USA Guido van den Berk; Josephine Oryszczyn;Willem Blok; Narda van der Meche; Rosa Regez; Daoud Ait Moha; Kees Brinkman OLVGHosp,Amsterdam,Netherlands 949 Association of Antiretroviral Use and Abnormal Uterine Bleeding inWomenWith HIV ChristinaValiaveettil 1 ; Sheila Caddy 2 ; MarkYudin 3 ; Anita Benoit 4 ; Erin Ding 5 ; Angela Kaida 6 ; Alexandra de Pokomandy 7 ; Robert S. Hogg 6 ; Mona Loutfy 4 1 UnivofToronto,Toronto,ON,Canada; 2 SouthHlthCampus,Calgary, AB,Canada; 3 StMichael’sHosp,Toronto,ON,Canada; 4 Women’sColl Rsr Inst,UnivofToronto,Toronto,ON,Canada; 5 BritishColumbiaCntr forExcellence inHIV/AIDS,Vancouver,BC,Canada; 6 SimonFraserUniv, Burnaby,BC,Canada; 7 McGillUnivHlthCntr,Montréal,QC,Canada Stéphanie Raymond ; Romain Carcenac; Florence Nicot; Nicolas Jeanne; Michelle Cazabat; Mary Requena; Lise Cuzin; Pierre Delobel; Jacques Izopet CHUToulouse,Toulouse,France 951 Failure Rate in NRTI-Free Treatment Is Higher in 2 Compared to 3 Class Regimens Alexandra Scherrer 1 ; Jürg Böni 2 ; SabineYerly 3 ;Thomas Klimkait 4 ; Vincent Aubert 5 ; Matthias Cavassini 6 ; Manuel Battegay 7 ; Christoph Hauser 8 ; Enos Bernasconi 9 ; Huldrych F. Günthard 10 ; for the Swiss HIV Cohort Study 1 UnivHospZürich,Zürich,Switzerland; 2 InstofMedVirology,SwissNatl Cntr forRetroviruses,Zurich,Switzerland; 3 GenevaUnivHosp,Geneva, Switzerland; 4 UnivofBasel,Basel,Switzerland; 5 UnivHospLausanne, Lausanne,Switzerland; 6 UnivHospLausanne,UnivofLausanne, Lausanne,Switzerland; 7 UnivHospBasel,Basel,Switzerland; 8 Bern UnivHospandUnivofBern,Bern,Switzerland; 9 RegionalHospLugano, Lugano,Switzerland; 10 UnivHospZurich,Zurich,Switzerland 952 The Impact of Medication Adherence on Virologic Failure in A5202 Robert A. Parker 1 ; Dustin J. Rabideau 1 ; Paul E. Sax 2 ; CamlinTierney 3 ; Eric Daar 4 ; Ann Collier 5 ; Elena Losina 2 ; Kenneth A. Freedberg 1 1 MassachusettsGeneralHosp,Boston,MA,USA; 2 BrighamandWomen's Hosp,HarvardMedSch,Boston,MA,USA; 3 HarvardSchofPH,Boston, MA,USA; 4 HarborUnivofCaliforniaLosAngelesMedCntr,Torrance,CA, USA; 5 UnivofWashington,Seattle,WA,USA 950 No Selection of X4 Viruses by Maraviroc in Cell Reservoirs in R5X4 HIV Infections 948 Unexpectedly High Rate of Intolerance for Dolutegravir in Real-Life Setting

Poster Listings

76

CROI 2016